1986
1990
1996
2000
2006
2010
2016
Explore the history of Celgene.
Scroll right to see Celgene history unfold. This timeline will take you from our founding through our exponential growth globally over the past three decades.
David Stirling, Ph.D. and Sol Barer, Ph.D. team up at Celanese Corporation, a chemical company.
Leadership
Celgene spins off from Celanese and becomes an independent biotechnology company.
Corporate
Celgene's initial public offering (IPO) on the NASDAQ exchange.
Financial
Celgene licenses patent for uses of thalidomide from Rockefeller University.
Product
Celgene scientists research and develop numerous compounds based on the structure of thalidomide.
Product
Dr. Sol Barer named President and Chief Operating Officer.
Leadership
Receives U.S. Food and Drug Administration (FDA) approval for expanded access to THALOMID (thalidomide).
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
John W. Jackson, who had worked at Merck and American Cyanamid, joins Celgene and is named Chief Executive Officer.
Leadership
Receives FDA additional approval to market THALOMID?.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene works with the FDA to develop the industry's first Risk Evaluation and Mitigation Strategy (REMS) to avoid embryo-fetal exposure.
Product
Bob Hugin joins Celgene from J.P. Morgan & Co. Inc and becomes Chief Financial Officer.
Leadership
New England Journal of Medicine publishes landmark paper on THALOMID? (thalidomide).
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene develops FOCALIN? with Novartis and receives FDA approval.
Product
Celgene acquires Anthrogenesis and renames the unit Celgene Cellular Theraputics (CCT).
Corporate
REVLIMID? (lenalidomide)—an IMiD? compound— is discovered and developed in Celgene's own labs and approved by the FDA.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
FOCALIN XR?, an extended release formulation developed with Novartis, is approved by the FDA for an additional use.
Product
Dr. Sol Barer becomes Chief Executive Officer.
Leadership
Completion of International Headquarters in Boudry, Switzerland.
Corporate
THALOMID? (thalidomide) plus dexamethasone receives FDA approval.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
FDA approves REVLIMID? (lenalidomide) plus dexamethasone.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
European Medicines Agency (EMA) and the Swiss Medic approves REVLIMID? (lenalidomide) plus dexamethasone for an additional use.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene acquires Pharmion and begins marketing VIDAZA.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Corporate
EMA approves VIDAZA?
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene and Acceleron Pharma announce research collaboration to develop therapies for cancer and other rare diseases.
Corporate
Bob Hugin becomes Celgene's Chief Executive Officer.
Leadership
Celgene acquires Gloucester Pharmaceuticals, and begins marketing ISTODAX? (romidepsin).
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Corporate
Celgene acquires Abraxis BioScience and gains rights to ABRAXANE? (paclitaxel protein-bound particles for injectable suspension).
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Corporate
Product
Celgene and Agios Pharmaceuticals, Inc. announce global strategic collaboration focused on targeting cancer metabolism.
Corporate
FDA approves ISTODAX? (romidepsin) for an additional use.
Please see full Prescribing Information, including CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
FDA approves ABRAXANE? (paclitaxel protein-bound particles for injectable suspension) for an additional use (alt: indication, patient population).
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
FDA approves IMiD? compound POMALYST? (pomalidomide).
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene and bluebird bio enter into strategic research collaboration to develop novel therapies in oncology.
Corporate
OTEZLA? (apremilast) is approved by the U.S. FDA
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
OTEZLA? (apremilast) is approved by the U.S. FDA for an additional use.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
FDA approves REVLIMID? (lenalidomide) plus dexamethasone for an additional use.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene acquires San Diego, CA based Receptos Inc., adding ozanimod - an investigational oral agent in Phase III trials for relapsing / remitting Multiple Sclerosis (RRMS) and Inflammatory Bowel Disease (IBD).
The safety and efficacy of the agent and/or uses under investigation has not been established. There is no guarantee that the agent will receive health authority approval or become commercially available in any country for the uses being investigated.
Product
Corporate
Celgene and Juno Therapeutics enter into strategic research collaboration focused on the development of CAR T therapies
Corporate
Mark Alles is promoted to Chief Executive Officer and Bob Hugin becomes Executive Chairman.
Leadership
REVLIMID? (lenalidomide) is approved by the European Commission for an additional use.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene and collaborative partner Juno Therapeutics received breakthrough designation for investigational drug JCAR017 from the U.S. FDA and Priority Medicines Eligibility from the EMA for relapsed/refractory DLBCL.
The safety and efficacy of the agent and/or uses under investigation has not been established. There is no guarantee that the agent will receive health authority approval or become commercial available in any country.
Product
The U.S. FDA and European Commission approve REVLIMID? (lenalidomide) plus dexamethasone for an additional use.
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Celgene launches IDHIFA? (enasidenib)
Please see full Prescribing Information, including Boxed WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
Product
Acquisition of IMPACT BioMedicines and their therapy fedratinib for patients with myelofibrosis.
The safety and efficacy of the agent and/or uses under investigation has not been established. There is no guarantee that the agent will receive health authority approval or become commercially available in any country for the uses being investigated.
Product
Corporate
Executive Chairman Bob Hugin Retires. Mark Alles appointed Chairman of the Board of Directors.
Leadership
Acquisition of Juno Therapeutics, advancing our strategy to become the preeminment leader in cellular immunotherapy.
Corporate
X
X